Biologically Active Small Molecules

A potent, selective, and competitive inhibitor of ATGL (IC₅₀ = 0.7 &muM) does not inhibit hormone-sensitive lipase, monoglyceride lipase, pancreatic lipase, lipoprotein lipase, or other lysophospholipases blocks lipolysis by ATGL in

An imidazole that potently antagonizes the &alpha2-adrenoceptor (Ki = 1.6 nM) shows selectivity over the &alpha1-adrenoceptor (Ki = 13,300 nM) and is a poor antagonist at a wide variety of other receptors and channels.

An imidazole that potently antagonizes the &alpha2-adrenoceptor (Ki = 1.6 nM) shows selectivity over the &alpha1-adrenoceptor (Ki = 13,300 nM) and is a poor antagonist at a wide variety of other receptors and channels.

An imidazole that potently antagonizes the &alpha2-adrenoceptor (Ki = 1.6 nM) shows selectivity over the &alpha1-adrenoceptor (Ki = 13,300 nM) and is a poor antagonist at a wide variety of other receptors and channels.

An imidazole that potently antagonizes the &alpha2-adrenoceptor (Ki = 1.6 nM) shows selectivity over the &alpha1-adrenoceptor (Ki = 13,300 nM) and is a poor antagonist at a wide variety of other receptors and channels.

An HMG-CoA reductase inhibitor that is effective in treating hypercholesterolemia and certain dyslipidemias reduces the production of LDL as well as inhibiting cholesterol synthesis metabolized by CYP3A4, prodrug several metabolites that are

An HMG-CoA reductase inhibitor that is effective in treating hypercholesterolemia and certain dyslipidemias reduces the production of LDL as well as inhibiting cholesterol synthesis metabolized by CYP3A4, prodrug several metabolites that are

An HMG-CoA reductase inhibitor that is effective in treating hypercholesterolemia and certain dyslipidemias reduces the production of LDL as well as inhibiting cholesterol synthesis metabolized by CYP3A4, prodrug several metabolites that are

An HMG-CoA reductase inhibitor that is effective in treating hypercholesterolemia and certain dyslipidemias reduces the production of LDL as well as inhibiting cholesterol synthesis metabolized by CYP3A4, prodrug several metabolites that are

An antifungal antibiotic that selectively inhibits succinate dehydrogenase (complex II IC50s = 12 and 3.7 nM in nematode and mammalian mitochondria, respectively, versus IC50s &gt 100 &muM for inhibition of complex I and complex III enzymes) has

A natural heteroglucoside that blocks mitochondrial ADP/ATP translocases, inhibiting oxidative phosphorylation.

A natural heteroglucoside that blocks mitochondrial ADP/ATP translocases, inhibiting oxidative phosphorylation.